SL
CTKB icon

Salomon & Ludwin’s Cytek Biosciences CTKB Stock Holding History

Salomon & Ludwin’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.28K Sell
279
-2,422
-90% -$10.3K ﹤0.01% 2002
2026
Q1 		$12.2K Buy
2,701
+2,241
+487% +$10.6K ﹤0.01% 1415
2025
Q4 		$2.4K Buy
460
+181
+65% +$840 ﹤0.01% 1970
2025
Q3 		$1.11K Buy
+279
New +$1.05K ﹤0.01% 2037

Other funds holding CTKB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Salomon & Ludwin's CTKB Position: Q2 2026 in Review

Salomon & Ludwin reduced its Cytek Biosciences (CTKB) stake by 90% in Q2 2026, selling an estimated $10.3K and leaving 279 shares worth $1.28K. The position accounts for ﹤0.01% of the portfolio, ranked #2002.

Salomon & Ludwin first reported a position in CTKB in Q3 2025 and has held it in 4 quarters since. The position peaked at $12.2K in Q1 2026. 155 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

  • Salomon & Ludwin held 279 shares of Cytek Biosciences worth $1.28K as of Q2 2026.
  • Salomon & Ludwin sold 2,422 Cytek Biosciences shares in Q2 2026, an estimated $10.3K.
  • Cytek Biosciences made up ﹤0.01% of Salomon & Ludwin's portfolio in Q2 2026, its #2002 holding.
  • Salomon & Ludwin first reported a position in Cytek Biosciences in Q3 2025 and has held it in 4 quarters since.
  • Salomon & Ludwin's Cytek Biosciences position peaked at $12.2K in Q1 2026.
  • 155 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Salomon & Ludwin's 13F filing for Q2 2026, filed 7 Aug 2026.